# Nautilus Neurosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nautilus-neurosciences

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.nautilusneurosciences.com
- Total disclosed funding: $25M
- Latest round: Series A (Apr 13, 2010)
- Investors on record: 2

## About

Nautilus Neurosciences Inc is a biotechnology firm focused on developing and commercializing innovative therapeutic solutions for neurological conditions, aiming to enhance patient outcomes through advanced medical products.Founded in 2009 in the United States, Nautilus Neurosciences Inc specializes in neurological treatments. The company underwent a significant pivot in 2013 when it sold the rights to its product CAMBIA (diclofenac potassium for oral solution) to Depomed, Inc. for USD 48.7 mn. The total amount raised by the company up to this point is USD 48.7 mn from this TRADE SALE.Nautilus Neurosciences Inc offers a range of therapeutic products focused on addressing challenges in neurological healthcare. Its core offerings include specialized pharmaceutical solutions targeting conditions like migraine, which are designed to improve treatment efficacy and patient quality of life. The company has established its presence in North America and is also exploring opportunities in European and select Asian markets, aiming to cater to a global patient population.The revenue model of Nautilus Neurosciences Inc is primarily based on direct sales of its pharmaceutical products to healthcare providers and patients. This model allows the company to maintain flexibility and adapt to market demands while addressing specific therapeutic needs through its offerings. The pricing structure is designed to accommodate various healthcare systems and patient segments, ensuring accessibility to its innovative solutions.Looking ahead, Nautilus Neurosciences Inc plans to expand its product pipeline by developing new therapeutic solutions for additional neurological conditions, with anticipated releases in the coming years. The firm is also targeting growth in European markets, aiming to establish a more significant presence by 2025. The proceeds from the most recent deal, which was completed in December 2013, will be utilized to support these initiatives, including research and development for new product launches.

## Funding rounds

- Series A, Apr 13, 2010, $11M — Galen Partners
- Series A, Mar 11, 2010, $15M — Tailwind Capital

## Investors

- Tailwind Capital (https://capitalatlas.ai/funds/tailwind-capital) — Series A
- Galen Partners (https://capitalatlas.ai/funds/galen-partners) — Series A